SureTrader Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 4/28/2016 8:48:19 PM - Followers: 141 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#3450   And now we know why shorts have slowly The Other Guy 04/28/16 08:48:19 PM
#3449   Completely agree. Now it's a matter of The The Other Guy 04/28/16 08:46:06 PM
#3448   Not only that, but corneal scarring is an Inoviorulez 04/28/16 07:24:49 PM
#3447   After today news about advanced cornea scar in wildbullus 04/28/16 07:22:08 PM
#3446   Another aspect of today's PR is the recognition The Other Guy 04/28/16 07:12:13 PM
#3445   That is good thought, this should be considered wildbullus 04/28/16 06:01:13 PM
#3444   Monday morning should have a PR about maintaining Inoviorulez 04/28/16 05:56:46 PM
#3443   Should be fine. I hope all the catalysts Inoviorulez 04/28/16 05:56:05 PM
#3442   One more day. The Other Guy 04/28/16 04:01:55 PM
#3441   RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise Inoviorulez 04/28/16 07:09:42 AM
#3440   Yea.... Right.... They need a partnership even if million_dollar_mafia 04/27/16 08:55:27 PM
#3439   It's good to see that nobody is shorting Inoviorulez 04/27/16 07:37:26 PM
#3438   Yeah, it's hard to say. If the RS The Other Guy 04/27/16 02:14:34 PM
#3437   Let's hope these were the reasons why Geert Titan V 04/27/16 01:27:25 PM
#3436   Agreed. Low OS, decreasing short interest, increasing institutional The Other Guy 04/27/16 12:22:08 PM
#3435   I missed that, sorry. With the low OS, Titan V 04/27/16 11:53:44 AM
#3434   As stated in the post, the stat is The Other Guy 04/27/16 11:50:24 AM
#3433   The stat might not be reflective of new Titan V 04/27/16 11:41:58 AM
#3432   Short interest (last reported prior to RS) dropped The Other Guy 04/27/16 09:49:41 AM
#3431   RXi Pharmaceuticals to Webcast First Quarter 2016 Financial Inoviorulez 04/27/16 07:07:22 AM
#3430   It's oversold right now natural rally. But all million_dollar_mafia 04/26/16 09:33:29 PM
#3429   This won't hold with fluff prs million_dollar_mafia 04/26/16 09:32:57 PM
#3428   II has increased to 21.19%. Trying to find The Other Guy 04/26/16 05:37:41 PM
#3427   $30 stock price is $195M market cap. Considering The Other Guy 04/26/16 04:27:25 PM
#3426   On another site I saw year end target cinders118 04/26/16 03:27:12 PM
#3425   Now I understand why Geert only did R/S wildbullus 04/26/16 02:57:43 PM
#3424   While I applaud the effort management is making The Other Guy 04/26/16 09:40:12 AM
#3423   This presentation is important! It is the wildbullus 04/26/16 08:08:21 AM
#3422   Think this will sto p the bleeding? Bah million_dollar_mafia 04/26/16 07:18:12 AM
#3421   RXi Pharmaceuticals Announces 'Biotech Spotlight' Presentation at the Inoviorulez 04/26/16 07:15:03 AM
#3420   Shoulda split more million_dollar_mafia 04/25/16 08:00:09 PM
#3419   In the past six days, the PPS dropped wildbullus 04/25/16 06:22:44 PM
#3418   Wow PPS has been dropping fast since RS InternetForumUser 04/25/16 10:32:14 AM
#3417   RXi Pharmaceuticals to Present at 18th Annual TIDES: Inoviorulez 04/25/16 07:10:25 AM
#3416   So my bank statements look real sad compared million_dollar_mafia 04/23/16 06:37:42 PM
#3415   Instead of fortifying their parents they should fortify million_dollar_mafia 04/22/16 10:08:03 PM
#3414   At $1 the market cap would be $6.5 The Other Guy 04/22/16 11:48:15 AM
#3413   Hope the share price can hold above $1 wildbullus 04/22/16 11:08:54 AM
#3412   Yea not looking good million_dollar_mafia 04/22/16 09:58:25 AM
#3411   Lol million_dollar_mafia 04/21/16 11:16:39 PM
#3410   It is a Poster and not a formal presentation. InternetForumUser 04/21/16 09:06:00 PM
#3409   Is the presentation really an hour and 45 Titan V 04/21/16 08:10:01 PM
#3408   ARVO conference presetation wildbullus 04/21/16 08:01:36 PM
#3407   With these small biotechs and other tech stocks microchips 04/21/16 02:38:55 PM
#3406   Just need to get through next week. But, The Other Guy 04/21/16 01:32:52 PM
#3405   At this rate the PPS will be under InternetForumUser 04/21/16 10:17:52 AM
#3404   2.02 million actually. The Other Guy 04/21/16 09:43:46 AM
#3403   There were 3 mil short pre split so million_dollar_mafia 04/20/16 10:02:30 PM
#3402   The reason for high short interest before was Inoviorulez 04/20/16 09:26:18 PM
#3401   The volume is encouraging. I am curious what The Other Guy 04/20/16 09:17:45 PM